Pharma News

Glenmark receives US FDA approval for norethindrone acetate and ethinyl estradiol tablets USP

  • Posted on: 9 April 2015
  • By: admin

Glenmark Generics Inc. USA, a subsidiary of Glenmark Generics, has received the final approval from the United States Food and Drug Administration (USFDA) for sale of drugs meant to prevent post-menopause osteoporosis.USFDA granted Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/2.5 mcg and 1 mg/5 mcg.

Live monitoring of fetal heart rate, First time in india

  • Posted on: 9 April 2015
  • By: admin

The cumbersome days of stressful, manual, wired monitoring of the unborn child in pregnant mothers will soon end - thanks to a new system unveiled at a hospital here. The Lokmanya Tilak Municipal General Hospital, known as the Sion Hospital, has introduced system in order to monitor the fetal heart rate and condition of the baby in the uterus of a pregnant lady for the first time in India.

Chemical to Trap Malaria Mosquitoes Identified

  • Posted on: 8 April 2015
  • By: admin

In a world first, researchers have found that a naturally occurring chemical attracts pregnant malaria transmitting mosquitoes - a discovery which could boost malaria control efforts. The chemical, cedrol, found in mosquito breeding sites near Africa's Lake Victoria, could be used in traps that would 'attract and kill' the female mosquito, preventing reproduction before she lays hundreds of eggs.

Vitamin D may Help Treat Age related Diseases

Vitamin D may play a vital role in the prevention and treatment of chronic diseases associated with ageing such as diabetes and cancer, according to new research. Researchers reviewed evidence that suggests an association between vitamin D deficiency and chronic diseases associated with ageing such as cognitive decline, depression, osteoporosis, cardiovascular disease, high blood pressure, Type 2 diabetes and cancer.

In US, Up to 2020, RA treatment market value to reach $9.3 bn

  • Posted on: 7 April 2015
  • By: admin

According to business intelligence provider GBI (GlobalBusinessIntelligence) Research In 2013,  The US treatment market for rheumatoid arthritis (RA) was $6.4 billion and which get rising to $9.3 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.5%. Resaon behind this sudden growth  is US’ increasing prevalent population, which is reported  to hit 1.68 million by 2020. Consequently, marketcurrently makes up the  largest treatmentarea of the eight major pharmaceutical markets (the US, UK, Canada, France, Germany, Spain, Italy and Japan).

Pages